您的购物车内没有物品。
微信关注FLT3
Inhibitory Selectivity
| Catalog No. | Inhibitor Name | FLT3 | Other |
|---|---|---|---|
| A10996 | Cabozantinib | ** | VEGFR2/KDR,c-Met,Kit |
| A10027 | Quizartinib | *** | |
| A11411 | Dovitinib | **** | c-Kit,VEGFR3/FLT4,FGFR1 |
| A10610 | Amuvatinib | * | c-Kit (D816H),PDGFRα (V561D) |
| A10887 | Tandutinib | * | c-Kit,PDGFRβ,CSF-1R |
| A11180 | TG101209 | * | JAK2,RET,JAK3 |
| A10508 | KW-2449 | **** | Abl (T315I),Abl,FGFR1 |
| A10352 | ENMD-2076 | *** | RET,Aurora A,VEGFR3/FLT4 |
| A10198 | Dovitinib Dilactic Acid | **** | c-Kit,FGFR1,VEGFR3/FLT4 |
| A12694 | Pacritinib | ** | JAK2 (V617F),JAK2,TYK2 |
| A12427 | TCS 359 | * | |
| A10352 | ENMD-2076 L-(*)-Tartaric acid | RET,Aurora A,VEGFR3/FLT4 | |
| A15904 | UNC2025 | **** | Mer |
| A14025 | AMG 925 | **** | CDK4,CDK1 |
| A14214 | G-749 | **** | Mer,Aurora B,RET |
| A14156 | AZD2932 | PDGFRβ,VEGFR-2,c-Kit | |
| A10769 | R406 | Syk | |
| A12419 | Go6976 | JAK2,PKCα,PKCβ1 | |
| A11962 | TG-02 (SB1317) | * | CDK2, JAK2 |
| A14411 | Gilteritinib (ASP2215) | **** | Axl |
| A15003 | AST 487 | Ret, c-Kit, KDR, c-Abl | |
| A15520 | Pexidartinib (PLX3397) | * | Kit, CSF-1R |
| A15548 | SU5614 | ||
| A16248 | BPR1J-097 | ** |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
28 个项目
每页
| Catalog No. | Product Name | Application | Product Information |
|---|---|---|---|
A10027 SALE |
AC220 (Quizartinib) |
FLT3 抑制剂 |
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively.
|
A11962 SALE |
TG-02 (SB1317) |
FLT3 抑制剂 |
TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.
|
A14214 |
G-749 |
FLT3 抑制剂 |
G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y).
|
A14411 |
Gilteritinib (ASP2215) |
FLT3/Axl 抑制剂 |
Gilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
|
A14025 |
AMG-925 |
Dual FLT3/CDK4 抑制剂 |
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
|
A15003 |
AST 487
|
RET kinase 抑制剂 |
AST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
|
A15520 SALE |
Pexidartinib (PLX3397) |
CSF1/Kit/FLT3 抑制剂 |
Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
|
A15548 SALE |
SU5614 |
FLT3 抑制剂 |
SU5614 is a potent and selective FLT3 inhibitor. SU5614 reverts the antiapoptotic and pro-proliferative activity of FLT3 ligand (FL) in FL-dependent cells.
|
A15904 |
UNC-2025 |
Dual MER/FLT3 抑制剂 |
UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
|
A16246 |
AC710 Mesylate |
FLT3/KIT/PDGFR??/PDGFR?? 抑制剂 |
AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
|
A16248 |
BPR1J-097 |
FLT3 抑制剂 |
BPR1J-097 is a novel small molecule FLT-3 inhibitor with promising in vivo anti-tumour activities.
|
A16249 |
FLT3-IN-1 |
FLT3 抑制剂 |
FLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.
|
A16250 |
FLT3-IN-2 |
FLT3 抑制剂 |
FLT3-IN-2 is potent FLT3 inhibitor.
|
A14156 |
AZD 2932 |
mutil-targeted protein tyrosine kinase 抑制剂 |
AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
|
A12694 SALE |
Pacritinib (SB1518) |
JAK2/FLT3 抑制剂 |
Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis.
|
A10996 SALE |
XL184 free base (Cabozantinib) |
VEGFR 抑制剂 |
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
|
A10769 SALE |
R406 besylate |
Syk 抑制剂 |
R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.
|
A11411 SALE |
Dovitinib (TKI-258) |
RTK 抑制剂 |
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
|
A10610 |
MP470 (MP-470, Amuvatinib) |
RTK 抑制剂 |
MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.
|
A10887 SALE |
Tandutinib (MLN518) |
FLT3 抑制剂 |
Tandutinib (MLN518) inhibits the autophosphorylation of FLT3, c-KIT and PDGF receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.
|
A10352 SALE |
ENMD-2076 |
Aurora A / FLT3 抑制剂 |
ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
|
A10508 SALE |
KW-2449 |
FLT3/FGFR/Bcr-Abl/Aurora 抑制剂 |
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
|
A11180 |
TG101209 |
JAK2 抑制剂 |
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. |
A10198 SALE |
Dovitinib Dilactic acid (TKI258 Dilactic acid) |
RTK 抑制剂 |
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
|
A11753 |
MK-2461 |
c-Met 抑制剂 |
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
|
A12419 |
Go 6976 |
PKC 抑制剂 |
Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
|
A12427 |
TCS 359 |
FLT3 抑制剂 |
TCS 359 is a potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases.
|
A10770 SALE |
R406 (Tamatinib) |
Syk 抑制剂 |
R406 is a potent inhibitor of immunoglobulin E (IgE)- and IgG-mediated activation of Fc receptor signaling.
|
28 个项目
每页
